Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Acyltransferase
    (1)
  • Amino Acids and Derivatives
    (1)
  • Apoptosis
    (2)
  • CCR
    (1)
  • COX
    (1)
  • DNA/RNA Synthesis
    (1)
  • Dehydrogenase
    (1)
  • Endogenous Metabolite
    (4)
  • NF-κB
    (2)
  • Others
    (32)
Filter
Search Result
Results for "

Non-alcoholic

" in TargetMol Product Catalog
  • Inhibitor Products
    54
    TargetMol | Activity
  • Recombinant Protein
    5
    TargetMol | inventory
  • Inhibitory Antibodies
    4
    TargetMol | natural
  • Natural Products
    4
    TargetMol | composition
  • Peptides Products
    2
    TargetMol | Activity
CX08005
T371841256341-22-6
CX08005 is a protein tyrosine phosphatase 1B inhibitor. CX08005 reduces hepatic lipid accumulation and microcirculatory impairment associated with non-alcoholic fatty liver disease.
  • $94
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Apararenone
T14301945966-46-1In house
Apararenone (MT-3995) is a receptor antagonist of mineralocorticoid receptor which can be used to treat non-alcoholic steatohepatitis and diabetic nephropathy.
  • $35
In Stock
Size
QTY
Vidofludimus
T2601717824-30-1
Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
  • $54
In Stock
Size
QTY
TargetMol | Citations Cited
Glycolithocholic acid
T31964474-74-8
Glycolithocholic acid (Lithocholic acid glycine conjugate) is a glycine conjugate of lithocholic acid.
  • $33
In Stock
Size
QTY
TargetMol | Citations Cited
GSK-LSD1
T822541431368-48-7
GSK-LSD1, an LSD1 inhibitor, decreases food consumption and body weight while enhancing insulin sensitivity and glycemic regulation in murine obesity models. Additionally, it mitigates non-alcoholic fatty liver disease (NAFLD) and suppresses cytokine release induced by SARS-CoV-2 in COVID-19 peripheral blood mononuclear cells (PBMCs). Furthermore, GSK-LSD1 inhibits the proliferation and spread of cancer [1] [2] [3].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
1-Palmitoyl-sn-glycerol 3-phosphate
T834217220-34-0
1-Palmitoyl-sn-glycerol 3-phosphate (1-P-GPA), an endogenous metabolite, is utilized in the research of non-alcoholic fatty liver disease [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
1-Palmitoyl-2-Stearoyl-3-Oleoyl-rac-glycerol
T354432190-28-5
1-Palmitoyl-2-stearoyl-3-oleoyl-rac-glycerol is a triacylglycerol that contains palmitic , stearic , and oleic acid at the sn-1, sn-2, and sn-3 positions, respectively. It has been detected in RAW 264.7 cells by neutral loss MS. Increased serum levels of 1-palmitoyl-2-stearoyl-3-oleoyl-rac-glycerol are a potential biomarker for non-alcoholic fatty liver disease (NAFLD).
  • $93
35 days
Size
QTY
TargetMol | Inhibitor Sale
Efruxifermin
T771752375240-92-7
Efruxifermin, an Fc-FGF21 fusion protein consisting of a human IgG1 Fc domain linked to modified human FGF21, exhibits a prolonged half-life and enhanced receptor affinity compared to its native counterpart. It is utilized in researching non-alcoholic steatohepatitis [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Ajoene
T3562492285-01-3
Ajoene is a disulfide that has been found inA. sativumand has diverse biological activities, including antibacterial, anticancer, antiplatelet, and antioxidant properties.1,2,3,4It is active against Gram-positive (MICs = 5-160 µg/ml) and Gram-negative bacteria (MICs = 136-200 µg/ml), as well as yeasts (MICs = 10-20 µg/ml).1Ajoene is cytotoxic to mouse melanoma cells (IC50= 18 µM), as well as human colon, lung, mammary, and pancreatic cancer cells (IC50s = 7-41 µM).2It reduces tumor growth in a B16/BL6 mouse model of melanoma when administered at a dose of 25 mg/kg every other day and decreases the number of lung metastases when administered prior to tumor cell inoculation at doses ranging from 1-25 mg/kg. It inhibits ADP- or collagen-induced platelet aggregation in isolated baboon platelets when used at concentrations ranging from 75 to 150 µg/ml and in platelet-rich plasma isolated from baboons when administered at a dose of 25 mg/kg.3Ajoene (25 mg/kg) prevents thrombus formation on damaged arterial walls in heparinized pigs in anin situmodel of thrombogenesis.5It also reduces high-fat diet-induced hepatic steatosis, histopathological markers of liver damage, thiobarbituric acid reactive substances (TBARS) formation, and protein oxidation in a mouse model of non-alcoholic fatty liver disease (NAFLD).4 1.Naganawa, R., Iwata, N., Ishikawa, K., et al.Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlicAppl. Environ. Microbiol.62(11)4238-4242(1996) 2.Taylor, P., Noriega, R., Farah, C., et al.Ajoene inhibits both primary tumor growth and metastasis of B16/BL6 melanoma cells in C57BL/6 miceCancer Lett.239(2)298-304(2006) 3.Teranishi, K., Apitz-Castro, R., Robson, S.C., et al.Inhibition of baboon platelet aggregation in vitro and in vivo by the garlic derivative, ajoeneXenotransplantation10(4)374-379(2003) 4.Han, C.Y., Ki, S.H., Kim, Y.W., et al.Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activationAntioxid. Redox Signal.14(2)187-202(2011) 5.Apitz-Castro, R., Badimon, J.J., and Badimon, L.A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel wall in an in vivo porcine experimental modelThromb. Res.75(3)243-249(1994)
  • $1,520
Backorder
Size
QTY
TargetMol | Inhibitor Sale
MGAT2-IN-4
T818021841424-92-7
MGAT2-IN-4 (compound 33) serves as a monoacylglycerol acyltransferase 2 (MGAT2) inhibitor, exhibiting liver metabolic stability. This compound is applicable in obesity, diabetes, and non-alcoholic steatohepatitis (NASH) research [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Nimacimab
T770992098636-09-8
Nimacimab is a recombinant humanized monoclonal antibody. It can improve diabetes and non-alcoholic steatohepatitis.
  • $238
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PTUPB
T125801287761-01-6
PTUPB is a potent and dual inhibitor of sEH and COX-2 enzymes(IC50 of 0.9 nM and 1.26 μM, respectively).
  • $135
In Stock
Size
QTY
TargetMol | Inhibitor Sale
BMS-986172
T828481808258-99-2
BMS-986172 is an orally active, highly selective inhibitor of MGAT2, demonstrating inhibitory concentrations (IC50) of 4.6 nM for human MGAT2 (hMGAT2) and 20 nM for mouse MGAT2 (mMGAT2). It exhibits a half-life (T1/2) greater than 120 minutes in vitro and is known to decrease food intake and body weight. This compound is considered promising for the research of metabolic disorders, including obesity and non-alcoholic steatohepatitis (NASH) [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Pemvidutide
T744212538014-94-5
Pemvidutide, a dual GLP-1R/GCGR agonist, significantly lowers body weight, liver fat, and serum lipids, holding promise for non-alcoholic steatohepatitis (NASH) and obesity research [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Volixibat
T172361025216-57-2
Volixibat is a highly selective and competitive apical sodium-dependent bile acid transporter inhibitor. Volixibat has the potential for treatment for non-alcoholic steatohepatitis.
  • $1,520
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Simtuzumab
T767001318075-13-6
Simtuzumab is a monoclonal antibody against lysyl oxidase-like protein 2 (LOXL2). Simtuzumab can be used to treat primary sclerosing cholangitis (PSC) and is not effective in patients with bridging fibrosis or compensatory cirrhosis caused by non-alcoholic steatohepatitis.
  • $222
In Stock
Size
QTY
TargetMol | Inhibitor Sale
FXR agonist 3
T74996
FXR agonist 3, an anti-NASH (Non-Alcoholic Steatohepatitis) agent, functions by activating FXR. It demonstrates anti-fibrogenic activity by inhibiting the expression of COL1A1, TGF-β1, α-SMA, and TIMP1. Additionally, it significantly mitigates liver steatosis and inflammation and enhances the liver fibrosis level [1].
  • $136
7-10 days
Size
QTY
TargetMol | Inhibitor Sale
Cisd2 agonist 1
T780932916371-54-3
Cisd2 agonist 1 (Compound 4q), with an EC50 of 34 nM, augments Cisd2 expression and ameliorates pathological alterations in fatty liver disease, demonstrating good metabolic stability. This compound is utilized in non-alcoholic fatty liver disease (NAFLD) research[1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
INT-767
T116611000403-03-1
INT-767 is a potent farnesoid X receptor (FXR)/TGR5 dual agonist that prevents NASH and promotes visceral adipose brown lipogenesis and mitochondrial function for the study of non-alcoholic steatohepatitis.
  • $399
In Stock
Size
QTY
H-Asp(OtBu)-OtBu HCl
T658151791-13-5
H-Asp(OtBu)-OtBu HCl is an aspartic acid derivative that may be used to study comparative neurological function and metabolic disorders of non-alcoholic hepatitis.
  • $29
In Stock
Size
QTY
ZLY032
T358162314465-67-1
ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob/obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. 1.Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019) 2.Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)
  • $110
35 days
Size
QTY
FXR antagonist 1
T641442295804-68-9
FXR antagonist 1 is a selective, orally active intestinal FXR antagonist with an IC50 value of 2.1 μM. FXR antagonist 1 antagonises intestinal FXR and selectively inhibits intestinal FXR signalling by feedback activation of hepatic FXR. FXR antagonist 1 can improve liver steatosis, inflammation and fibrosis in the NASH (non-alcoholic steatohepatitis) model and can be used to study NASH.
  • $1,520
8-10 weeks
Size
QTY
Ervogastat
T91862186700-33-2
Ervogastat (PF-06865571) is a potent and well-tolerated diacylglycerol acyltransferase 2 inhibitor. Ervogastat reduces steatosis and hepatic triglyceride levels in non-alcoholic steatohepatitis (NASH).
  • $132
In Stock
Size
QTY
GOAT-IN-1
T114481452473-54-9
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of diabetes, hyperlipidemia, non-alcoholic fatty liver, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral infa
  • $1,670
6-8 weeks
Size
QTY
2-Oleoylglycerol
T375263443-84-3
2-Oleoylglycerol is a lipid found in palm kernel, sunflower seed and rice bran.2-Oleoylglycerol acts as a GPR119 agonist with neuroprotective effects and induces secretion of glucagon-like peptide 1 (GLP-1).2-Oleoylglycerol is used in the modelling of non-alcoholic steatohepatitis.
  • $95
In Stock
Size
QTY
TargetMol | Inhibitor Sale
NSC 48160
T797836640-90-0
NSC 48160, a chemical compound, exhibits inhibitory effects on pancreatic cancer cell proliferation, with half-maximal inhibitory concentrations (IC50s) of 84.3 μM for CPFAC-1 and 94.5 μM for BxPC-3. It also promotes apoptosis in pancreatic cancer cells. Additionally, NSC 48160 has been shown to ameliorate metabolic syndromes, including non-alcoholic steatohepatitis (NASH), obesity, and lipid metabolism disorders [1] [2].
  • Inquiry Price
Size
QTY
S217879
T79698
S217879 is a potent and selective activator of NRF2 that disrupts the KEAP1-NRF2 interaction, resulting in significant activation of the NRF2 pathway. This compound is applicable in research on non-alcoholic steatohepatitis (NASH) [1].
  • Inquiry Price
Size
QTY
MBX-8025 (sodium salt)
T35799
MBX-8025 is an agonist of peroxisome proliferator-activated receptor δ (PPARδ).1 It is greater than 750- and 2,500-fold selective for PPARδ over PPARα and PPARγ. MBX-8025 (10 mg/kg per day for eight weeks) reduces increases in fasting blood glucose and serum insulin levels, and decreases insulin resistance in Alms1 mutant (foz/foz) mice fed an atherogenic diet as a model of diet-induced obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).2 It also decreases serum alanine transaminase (ALT), as well as serum and hepatic cholesterol and triglyceride, levels and reduces markers of NASH in the same model. |1. Bays, H.E., Schwartz, S., Littlejohn, T., 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-δ agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 96(9), 2889-2897 (2011).|2. Haczeyni, F., Wang, H., Barn, V., et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol. Commun. 1(7), 663-674 (2017).
  • $88
35 days
Size
QTY
Glycolithocholic acid, sodium salt
T6433424404-83-9
Glycolithocholic acid sodium salt, the sodium form of Glycolithocholic acid, is a glycine-conjugated secondary bile acid utilized in diagnosing ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH), and primary sclerosing cholangitis (PSC).
  • $33
In Stock
Size
QTY
SHS4121705
T356362379550-82-8
SHS4121705 is an orally bioavailable mitochondrial uncoupler.1It increases oxygen consumption rate in L6 rat myoblast cells with an EC50value of 4.3 μM. SHS4121705 (25 mg/kg per day in the diet) reduces hepatic steatosis, liver triglyceride levels, and plasma alanine aminotransferase (ALT) levels in Stelic animal model (STAM) mice, a model of non-alcoholic steatohepatitis (NASH). 1.Salamoun, J.M., Garcia, C.J., Hargett, S.R., et al.6-Amino[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol derivatives as efficacious mitochondrial uncouplers in STAM mouse model of nonalcoholic steatohepatitisJ. Med. Chem.63(11)6203-6224(2020)
  • $293
35 days
Size
QTY
CP-24879 hydrochloride
T2706110141-51-2
CP-24879 hydrochloride (CP-24879 HCl), a Δ5D/Δ6D dual-inhibitor, can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 hydrochloride exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes.
  • $42
In Stock
Size
QTY
PPARα/δ agonist 1
T629682760128-48-9
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist with EC50 values of 7.0 nM for PPARα and 8.4 nM for PPARδ. PPARα/δ agonist 1 exhibits high selectivity for PPARγ (EC50: 1316.1 nM). agonist 1 has potential for non-alcoholic steatohepatitis studies.
  • $1,520
6-8 weeks
Size
QTY
Demethyleneberberine chloride
T7809516705-03-6
Demethyleneberberine chloride, a natural mitochondria-targeted antioxidant, mitigates colitis in mice and suppresses inflammatory responses by blocking the NF-κB pathway and modulating the equilibrium of Th cells. It is also recognized as an AMPK activator for investigating non-alcoholic fatty liver disease (NAFLD) [1] [2] [3].
  • Inquiry Price
Size
QTY
PF-07247685
T79358
PF-07247685, a potent BCKDC kinase (BDK) inhibitor (EC 50 = 2.2 nM), enhances the binding between BDK and the BCKDH E2 core subunit to block E1 phosphorylation. BDK regulation is crucial for BCKDH activity, which manages the rate-limiting step in the catabolism of branched-chain amino acids (BCAA). Dysfunctional BCAA metabolism is linked to various cardiometabolic disorders such as heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 has demonstrated an ability to improve cardiometabolic parameters and glucose tolerance in mice [1].
  • Inquiry Price
Size
QTY
Murideoxycholic Acid
T37997668-49-5
Murideoxycholic Acid alleviates non-alcoholic fatty liver disease by modulating the enterohepatic axis.
  • $399
In Stock
Size
QTY
EDP-305
T734141933507-63-1
EDP-305, an orally active, potent, and selective agonist of the farnesoid X receptor (FXR), exhibits EC50 values of 34 nM in chimeric FXR within CHO cells and 8 nM in full-length FXR in HEK cells. Demonstrating a potent and consistent antifibrotic effect, EDP-305 is utilized in research related to primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH).
  • $1,230
6-8 weeks
Size
QTY
Leronlimab
T77059674782-26-4
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. leronlimumab has both anti-HIV and anti-tumor activity, inhibiting CCR-mediated HIV-1 virus and cancer cell metastasis in mouse tumor models. Leronlimab can be used to study HIV non-alcoholic steatohepatitis (NASH) and breast cancer.
  • $198
In Stock
Size
QTY
TargetMol | Inhibitor Sale
DB1976 dihydrochloride
T10964L2369663-93-2
DB1976 dihydrochloride (DB1976 2HCl) , a transcription factor PU.1 inhibitor with potential anti-inflammatory activity, slowed down inflammation and fibrosis and improved glucose homeostasis and dyslipidemia in mice in in vivo experiments.DB1976 dihydrochloride promotes apoptosis and may be used in studies of metabolic dysfunction and non-alcoholic steatohepatitis.
  • $390
1-2 weeks
Size
QTY
Pemvidutide TFA
T78658
Pemvidutide (TFA), a GLP-1R/GCGR dual agonist, effectively reduces body weight, liver fat, and serum lipid levels, and is utilized in research on non-alcoholic steatohepatitis (NASH) and obesity [1].
  • Inquiry Price
Size
QTY
PF-07238025
T79357
PF-07238025, a potent branched-chain ketoacid dehydrogenase kinase (BDK) inhibitor with an EC50 of 19 nM, enhances the stability of the BDK-BCKDH core E2 subunit interaction and inhibits the phosphorylation of the E1 subunit. By modulating BDK, which regulates the phosphorylation of BCKDH, a key enzyme in branched-chain amino acid (BCAA) degradation, PF-07238025 indirectly controls the rate-limiting step in BCAA catabolism. Dysregulated BCAA metabolism is implicated in various cardiometabolic disorders such as heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. Notably, PF-07238025 has been shown to ameliorate cardiometabolic endpoints and enhance glucose tolerance in mouse models [1].
  • Inquiry Price
Size
QTY
3-Epideoxycholic Acid
T84944570-63-8
3-Epideoxycholic acid (EDCA), a secondary bile acid and an epimer of deoxycholic acid, serves as a steroidal host compound in the enantioselective purification of (2R,3S)-3-methyl-2-pentanol from its racemates via enclathration. Additionally, decreased fecal levels of EDCA have been observed in pediatric patients with non-alcoholic fatty liver disease (NAFLD).
  • Inquiry Price
Size
QTY
ML261
T62029902523-58-4
ML261 is a inhibitor of hepatic lipid droplets formation with an IC 50 of 69.7 nM. ML261 has research value in non-alcoholic fatty liver disease (NAFLD) and inflammation.
  • $93
35 days
Size
QTY
FXR agonist 4
T72889
FXR agonist 4 with an EC 50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
  • $1,520
6-8 weeks
Size
QTY
QH536
T637772754254-07-2
QH536 is an effective degrader of HMGCR (EC50: 0.22 μM).QH536 exhibits anti-inflammatory effects and does not have the side effect of inducing intracellular accumulation of cholesterol.QH536 can be used to study cardiovascular disease and non-alcoholic steatohepatitis.
  • $1,520
8-10 weeks
Size
QTY
THR-β agonist 4
T635152673409-25-9
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has shown research potential for metabolic diseases such as hyperlipidemia, obesity, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases.
  • $2,140
10-14 weeks
Size
QTY
Teneligliptin
T37522760937-92-6
Teneligliptin (MP-513) is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM. Teneligliptin (MP-513) inhibits all these DPP-4 enzymes in a concentration-dependent manner. The IC50s of Teneligliptin (MP-513) for rhDPP-4, human plasma, and rat plasma are 0.889, 1.75, and 1.35 nM, respectively. A study of enzyme inhibition kinetics is conducted for Teneligliptin (MP-513) using Gly-Pro-MCA as the substrate and rhDPP-4 as the enzyme source. Plots based on the Michaelis-Menten equation reveals that Teneligliptin (MP-513) inhibits DPP-4 in a substrate-competitivemanner; the residual sum of squares for competitive and non-competitive models is 0.162 and 0.192, respectively. Ki, Km, and Vmax values are 0.406 nM, 24 μM, and 6.06 nmol/min, respectively. Teneligliptin (MP-513) inhibits the degradation of GLP-1(7-36)amide with an IC50 of 2.92 nM[1]. Oral administration of Teneligliptin (MP-513) in Wistar rats results in the inhibition of plasma DPP-4 with an ED50 of 0.41 mg/kg. Plasma DPP-4 inhibition is sustained even at 24 h after administration of Teneligliptin (MP-513). An oral carbohydrate-loading test in Zucker fatty rats shows that Teneligliptin (MP-513) at ≥0.1 mg/kg increases the maximum increase in plasmaglucagon-like peptide-1 and insulin levels, and reduces glucose excursions. This effect is observed over 12 h after a dose of 1 mg/kg. An oral fat-loading test in Zucker fatty rats also shows that Teneligliptin (MP-513) at 1 mg/kg reduces triglyceride and free fatty acid excursions. In Zucker fatty rats, repeated administration of Teneligliptin (MP-513) for two weeks reduces glucose excursions in the oral carbohydrate-loading test and decreased the plasma levels of triglycerides and free fatty acids under non-fasting conditions. Oral administration of Teneligliptin (MP-513) inhibits plasma DPP-4 in rats in a dose-dependent manner. The ED50 value for Teneligliptin (MP-513) is calculated to be 0.41 mg/kg, while those for Sitagliptin and Vildagliptin, 27.3 and 12.8 mg/kg, respectively[1]. Teneligliptin (MP-513) improves the histopathological appearance of the liver and decreases intrahepatic triglyceride levels in an NAFLD model mouse, which is associated with downregulation of hepatic lipogenesis-related genes due to AMPK activation[2]. [1]. Fukuda-Tsuru S, et al. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202. [2]. Ideta T, et al. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci. 2015 Dec 8;16(12):29207-18.
  • $30
7-10 days
Size
QTY
THR-β agonist 3
T636972656400-84-7
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has shown research potential for metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases.
  • $1,520
8-10 weeks
Size
QTY
AMPK activator 6
T62052189299-03-4
AMPK activator 6 (Compound GC) activates the AMPK pathway and reduces lipid content in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase of total cholesterol (TC), low-density lipoprotein-C (LDL-C), triglyceride (TG), and other biochemical indices in blood serum. AMPK activator 6 has research value in non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
  • $2,140
6-8 weeks
Size
QTY
NLRP3-IN-20
T797332428478-22-0
NLRP3-IN-20 (compound 11) is an orally administered inhibitor targeting the NLRP3 inflammasome, exhibiting potent inhibition with an IC50 of 25 nM against IL-1β secretion. It possesses excellent pharmacokinetic properties and has shown significant efficacy in models of non-alcoholic steatohepatitis, fatal septic shock, and colitis [1].
  • $1,520
6-8 weeks
Size
QTY
Berberine ursodeoxycholate
T679741868138-66-2
Berberine ursodeoxycholate (HTD1801) is an orally effective hypolipidemic agent, an ionic salt of Berberine and Ursodeoxycholic acid.Berberine ursodeoxycholate has a wide range of metabolic activity and significantly reduces liver fat content. Berberine ursodeoxycholate has been used in studies of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes.
  • $32
In Stock
Size
QTY